Home / Business and Economy / Dr. Reddy's Unveils Affordable Cancer Treatment
Dr. Reddy's Unveils Affordable Cancer Treatment
13 Jun
Summary
- Generic Bosulif launched in the U.S. by Dr. Reddy's Laboratories.
- Company partnered with MSN Laboratories for development and manufacturing.
- Bosulif brand had $253.8 million in U.S. sales in April 2026.
Dr. Reddy's Laboratories announced on June 13, 2026, the launch of Bosutinib Tablets 400 mg in the United States. This marks the first-to-market generic equivalent of Wyeth's (a Pfizer subsidiary) cancer medication, Bosulif. The launch aims to enhance accessibility and affordability of vital cancer therapies.
This Bosutinib Tablets 400mg product was a first-to-file submission, making it eligible for 180-day generic drug exclusivity in the U.S. Dr. Reddy's collaborated with fellow Hyderabad-based firm MSN Laboratories for this venture. While Dr. Reddy's holds the exclusive marketing rights in the U.S., MSN is responsible for the product's development and manufacturing.
In the twelve months concluding April 2026, the original Bosulif brand achieved approximately $253.8 million in U.S. sales. According to the U.S. FDA, Bosulif is a kinase inhibitor used to treat adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML), as well as advanced stages of Ph+ CML resistant to prior treatments.
This successful development and commercialization underscore MSN's robust capabilities in handling complex oncology products, including scientific, regulatory, and manufacturing aspects. Dr. Reddy's leadership expressed a commitment to strengthening their oncology portfolio and partnering to ensure critical treatments are widely available.
